trial

A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia

NCTId NCT02624167
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 90 (actual)
Sponsored by Newron Pharmaceuticals SPA
Primary completion 2016-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
90 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2015-12
Primary completion
2016-12
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Evenamide

Sponsors

Newron Pharmaceuticals SPALead Sponsor

Investigators

1
Ravi Anand, MDStudy Director

Sites

5 total
Garden Grove, United StatesBerlin, United StatesChennai, IndiaMadurai, IndiaBangalore, India

Linked catalysts

1
A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients — primary completion2016-12

Facts & assertions

4 sourced
Enrollment
90
Phase
PHASE2
Primary Completion Date
2016-12
Status
COMPLETED
relationships
The graph out of here
drug
Evenamide
drug
lead_sponsor
Newron Pharmaceuticals SPA
company
indication
Chronic Schizophrenia
indication
investigator
Ravi Anand, MD
person